The Growth of Literature 2010
DOI: 10.1017/cbo9780511711008.002
|View full text |Cite
|
Sign up to set email alerts
|

Preface

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
10
0
2

Year Published

2011
2011
2019
2019

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(12 citation statements)
references
References 0 publications
0
10
0
2
Order By: Relevance
“…Noninferiority of the new treatment with respect to the reference treatment is of interest on the premise that the new treatment has some other advantage, such as greater availability, reduced cost, less invasiveness, 11,12 fewer adverse effects (harms), 13 or greater ease of administration. 14 In trials that investigate noninferiority, therefore, the question of interest is not symmetric.…”
Section: Rationale For Noninferiority or Equivalence Designsmentioning
confidence: 99%
“…Noninferiority of the new treatment with respect to the reference treatment is of interest on the premise that the new treatment has some other advantage, such as greater availability, reduced cost, less invasiveness, 11,12 fewer adverse effects (harms), 13 or greater ease of administration. 14 In trials that investigate noninferiority, therefore, the question of interest is not symmetric.…”
Section: Rationale For Noninferiority or Equivalence Designsmentioning
confidence: 99%
“…73,90,91 One double-blind study in partial epilepsy reported evidence of agitation (6%), depression (3%), and insomnia (2%), whereas a controlled study in generalized epilepsy found no evidence of increased depression, aggression, or neurosis with treatment. 92,93 The use of carbamazepine has been linked to improvements in obsessive compulsive and paranoid symptom profiles, and has demonstrated both positive and negative effects on cognitive performance in patients with Rolandic epilepsy. 94,95 Ethosuximide Ethosuximide is relatively well tolerated by pediatric epilepsy patients with few psychiatric adverse effects.…”
Section: Carbamazepinementioning
confidence: 99%
“…... Feb. 18,W,[21][22][23]25,26,[11][12][13]25,26,28,and Apr. 1,2,[4][5][6]8,9,11,[12][13][14][15][16][17][18][19][20]23,25,26,28,30 and May 1,2... ............ May 3,4,6,7,g,[11][12][13][14][15][16][17][18][20][21][22][23][24][16][17][18][6][7][8]…”
Section: Kiskiminetas Riverunclassified